Flumazenil de A 6R)-6-[(2R)-2-amino-2-phenylacetamido]-3

6R)-6-[(2R)-2-amino-2-phenylacetamido]-3

InChi: InChI=1S/C28H32N8O3/c1-38-28(37)31-22-6-4-21(5-7-22)25-32-26(35-13-15-39-16-14-35)24-18-30-36(27(24)33-25)23-8-11-34(12-9-23)19-20-3-2-10-29-17-20/h2-7

is a n orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity

Lysophosphatidic acid (LPA) is a bioactive phospholipid that signals through a family of at least six G protein-coupled receptors designated LPA1-6

InChi: InChI=1S/C50H74O14/c1-27-13-12-16-34-26-57-47-42(51)30(4)21-37(50(34

Flumazenil de A 6R)-6-[(2R)-2-amino-2-phenylacetamido]-3Flumazenil is a specific benzodiazepine receptor antagonist primarily administered by injection. It is the only benzodiazepine receptor antagonist on the market today. Flumazenil is of benefit in patients who become excessively drowsy after benzodiazepines are used for either diagnostic or therapeutic procedures and it has been used as an antidote in the treatment of benzodiazepine overdoses. Product information CAS Number: 78755 81 4 Molecular